FMC - El Dorado is a medicare approved dialysis facility center in El Dorado, Kansas and it has 12 dialysis stations. It is located in Butler county at 701 W. Central, El Dorado, KS, 67042. You can reach out to the office of FMC - El Dorado at (316) 322-4541. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC - El Dorado has the following ownership type - Non-Profit. It was first certified by medicare in October, 1999. The medicare id for this facility is 170017 and it accepts patients under medicare ESRD program.
| Name | FMC - El Dorado |
|---|---|
| Location | 701 W. Central, El Dorado, Kansas |
| No. of Dialysis Stations | 12 |
| Medicare ID | 170017 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 701 W. Central, El Dorado, Kansas, 67042 | |
| (316) 322-4541 | |
News Archive
Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.
The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.
One in four Americans in the hospital right now has a urinary catheter. One percent of them will get a urinary tract infection from that catheter.
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.
› Verified 1 days ago
| NPI Number | 1831207836 |
| Organization Name | Susan B. Allen Dialysis Center |
| Doing Business As | Susan B. Allen Memorial Hospital |
| Address | 701 W Central Ave El Dorado, Kansas, 67042 |
| Phone Number | (316) 322-3300 |
News Archive
Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.
The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.
One in four Americans in the hospital right now has a urinary catheter. One percent of them will get a urinary tract infection from that catheter.
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 17 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 24 |
News Archive
Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.
The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.
One in four Americans in the hospital right now has a urinary catheter. One percent of them will get a urinary tract infection from that catheter.
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 30 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 260 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.
The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.
One in four Americans in the hospital right now has a urinary catheter. One percent of them will get a urinary tract infection from that catheter.
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC - El Dorado with elevated calcium levels.
| Patients with hypercalcemia | 31 |
| Hypercalcemia patient months | 264 |
| Patients with Serumphosphor | 31 |
| Patients with Serumphosphor less than 3.5 mg/dL | 8 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 29 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 32 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 12 |
News Archive
Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.
The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.
One in four Americans in the hospital right now has a urinary catheter. One percent of them will get a urinary tract infection from that catheter.
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 31 |
| Patient months included in arterial venous fistula and catheter summaries | 244 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 82 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
News Archive
Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.
The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.
One in four Americans in the hospital right now has a urinary catheter. One percent of them will get a urinary tract infection from that catheter.
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 29 |
| Hospitalization Rate in facility | 134.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 327.8 |
| Hospitalization Rate: Lower Confidence Limit | 59.4 |
News Archive
Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.
The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.
One in four Americans in the hospital right now has a urinary catheter. One percent of them will get a urinary tract infection from that catheter.
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC - El Dorado were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 9.6 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 29.9 |
| Readmission Rate: Lower Confidence Limit | 1.4 |
News Archive
Unraveling the mechanism that ovarian cancer cells use to change normal cells around them into cells that promote tumor growth has identified several new targets for treatment of this deadly disease.
The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.
One in four Americans in the hospital right now has a urinary catheter. One percent of them will get a urinary tract infection from that catheter.
A Mayo Clinic discovery about a protein known as Dynamin-2 has thrown conventional wisdom for a loop. Finding the protein on the centrosome, a minute structure near a cell's nucleus, may lead to new strategies for stopping cancer growth.
Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.
› Verified 1 days ago